Sinovac Biotech Ltd.
SVA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $448 | $1,493 | $19,375 | $511 |
| % Growth | -70% | -92.3% | 3,694.4% | – |
| Cost of Goods Sold | $182 | $684 | $1,072 | $67 |
| Gross Profit | $267 | $808 | $18,303 | $443 |
| % Margin | 59.5% | 54.1% | 94.5% | 86.8% |
| R&D Expenses | $345 | $442 | $155 | $49 |
| G&A Expenses | $466 | $824 | $591 | $177 |
| SG&A Expenses | $466 | $824 | $591 | $177 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $813 | $1,269 | $748 | $228 |
| Operating Income | -$547 | -$466 | $17,553 | $216 |
| % Margin | -122% | -31.2% | 90.6% | 42.2% |
| Other Income/Exp. Net | $394 | $491 | $10 | $1 |
| Pre-Tax Income | -$153 | $25 | $17,563 | $217 |
| Tax Expense | $105 | -$63 | $3,104 | $31 |
| Net Income | -$100 | $114 | $8,467 | $110 |
| % Margin | -22.3% | 7.6% | 43.7% | 21.6% |
| EPS | -1.06 | 1.08 | 85.2 | 1.06 |
| % Growth | -198.1% | -98.7% | 7,937.7% | – |
| EPS Diluted | -1.06 | 1 | 74.27 | 0.97 |
| Weighted Avg Shares Out | 100 | 100 | 99 | 99 |
| Weighted Avg Shares Out Dil | 100 | 114 | 114 | 114 |
| Supplemental Information | – | – | – | – |
| Interest Income | $85 | $191 | $103 | $2 |
| Interest Expense | $2 | $1 | $3 | $1 |
| Depreciation & Amortization | $145 | $157 | $100 | $7 |
| EBITDA | -$6 | $183 | $17,653 | $222 |
| % Margin | -1.3% | 12.3% | 91.1% | 43.4% |